SOX9 expression in the tumours was significantly associated with better disease-free survival (P = 0.03), stratifying the patients into two prognostic groups characterized by a 5-year disease-free survival of 70% for patients with SOX9-positive tumours versus 56% for patients with SOX9-negative tumours (Figure 2(a)). The gene discussed is SOX9; the disease is neoplasm.